ITM Isotope Technologies Munich

ITM Isotope Technologies Munich SE is a privately held biotechnology and radiopharmaceutical group dedicated to the development, production, and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for cancer treatment. Since its establishment in 2004, ITM and its subsidiaries have built GMP manufacturing capabilities and a robust global supply network, providing novel first-class medical radioisotopes and generator platforms for next-generation targeted cancer diagnostics and therapies. In addition, ITM is developing a proprietary portfolio and expanding pipeline of targeted therapies at various stages of clinical development to address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma, bone metastases, and folate receptor α-positive tumors like lung cancer, ovarian cancer, or breast cancer.